Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Southeastern Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$2,418,699

694 payments

Through program year 2025, Southeastern Research Center LLC is reported as receiving $2,418,699 in research payments, across 694 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $580,345 139
2024 Research $319,964 57
2023 Research $195,254 80
2022 Research $304,519 105
2021 Research $573,969 142
2020 Research $282,770 145
2019 Research $161,878 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $791,269 308 payments
  2. GlaxoSmithKline, LLC. $589,390 158 payments
  3. Genentech, Inc. $557,995 66 payments
  4. United Therapeutics Corporation $154,645 71 payments
  5. Shionogi Inc $121,706 56 payments
  6. Insmed, Inc. $120,981 27 payments
  7. Amgen Inc. $55,665 1 payment
  8. Grifols Biologicals LLC $11,305 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $5,408 1 payment
  10. AbbVie, Inc. $4,680 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Ph III OLE of Astegolimab in COPD $453,320 38 payments
  2. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $401,998 121 payments
  3. A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm $284,567 14 payments
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $208,663 112 payments
  5. Evaluation of S-600918 in Adults With Refractory Chronic Cough $121,706 56 payments
  6. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $112,047 52 payments
  7. A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para $98,977 37 payments
  8. Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study $84,965 6 payments
  9. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $59,809 46 payments
  10. A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis $55,665 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record